113293-70-2

Basic information

• Product Name: 2,6-Dichloropyridine-4-carboxaldehyde
• Synonyms: 2,6-DICHLOROISONICOTINALDEHYDE;2,6-DICHLOROPYRIDINE-4-CARBOXALDEHYDE;2,6-DICHLORO-4-FORMYL PYRIDINE;2,6-DICHLORO-4-PYRIDINECARBOXALDEHYDE;2,6-Dichloro-4-formyl pyeidine;2,6-Dichloropyridine-4-carboxaldehyde ,98%;2,6-dichloro-3-forMylpyridine-4-carboxylic acid;6-dichloropyridine-4-carbaldehyde
• CAS NO: 113293-70-2
• Molecular Formula: C₆H₃Cl₂NO
• Molecular Weight: 176
• Product Categories: pharmacetical;Aldehydes;Pyridines
• Mol File: 113293-70-2.mol
• Article Data: 10

Chemical Properties

• Melting Point: 47-48°C
• Boiling Point: 276.685 °C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.489 g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.39±0.10(Predicted)
• CAS DataBase Reference: 2,6-Dichloropyridine-4-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Dichloropyridine-4-carboxaldehyde(113293-70-2)
• EPA Substance Registry System: 2,6-Dichloropyridine-4-carboxaldehyde(113293-70-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 113293-70-2(Hazardous Substances Data)

Usage

Chemical Properties

White to yellow solid

InChI:InChI=1/C6H3Cl2NO/c7-5-1-4(3-10)2-6(8)9-5/h1-3H

Upstream product

• 42521-08-4 2,6-dichloroisonicotinoyl chloride 
• 68-12-2 N,N-dimethyl-formamide 
• 42521-09-5 methyl 2,6-dichloroisonicotinate 
• 1604-14-4 2,6-dichloroisonicotinic acid ethyl ester 
• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 99-11-6 citrazinic acid 
• 2402-78-0 2,6-dichloropyridine 
• 101990-69-6 (2,6-dichloropyridin-4-yl)methanol 
• 2591-86-8 N-Formylpiperidine 

Downstream Products

• 101990-69-6 (2,6-dichloropyridin-4-yl)methanol 
• 1201675-01-5 2,6-dichloro-4-(difluoromethyl) pyridine 
• 1239363-46-2 (S)-6-chloro-N-[1-(4-fluorophenyl)ethyl]-4-(oxazol-5-yl)pyridin-2-amine 
• 1201673-40-6 tert-butyl 4-(2'-(cyclohexylamino)-4-(difluoromethyl)-2,4'-bipyridin-6-yl)piperazine-1-carboxylate 
• 1201673-57-5 cyclohexyl-(4-difluoromethyl-6-piperazin-1-yl[2,4']bipyridinyl-2'-yl)amine 
• 1390656-68-4 tert-butyl 4-(4-(7-(2,6-dichlorobenzyl)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-2-methylphenyl)piperazine-1-carboxylate 
• 1390656-67-3 tert-butyl 4-(4-(7-chloro-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-2-methylphenyl)piperazine-1-carboxylate 
• 1390656-27-5 7-(2-chlorophenoxy)-5-{[2-ethoxy-4-(piperidin-4-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4(3H)-one 
• 1390658-07-7 tert-butyl 4-(4-(7-chloro-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-3-ethoxyphenyl)piperidine-1-carboxylate 
• 1390656-26-4 (4-{[7-(2-chlorophenoxy)-4-hydroxypyrido[3,4-d]pyridazin-5-yl]amino}-3-methoxyphenyl)(pyrrolidin-1-yl)methanone 
• 1390658-04-4 7-chloro-5-(2-methoxy-4-(pyrrolidine-1-carbonyl)phenylamino)pyrido[3,4-d]pyridazin-4(3H)-one 
• 1390656-17-3 5-{[2-chloro-4-(pyrrolidin-1-ylmethyl)phenyl]amino}-7-(3-hydroxyazetidin-1-yl)pyrido[3,4-d]pyridazin-4(3H)-one 
• 1390656-16-2 5-{[2-chloro-4-(pyrrolidin-1-ylmethyl)phenyl]amino}-7-(4-hydroxypiperidin-1-yl)pyrido[3,4-d]pyridazin-4(3H)-one 

Relevant articles and documents

Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity

To obtain a new anticancer drug, we focused on FER tyrosine kinase. Starting with high-throughput screening with our in-house chemical library, compound 1, which has a pyridine moiety, was found. Referring to their X-ray crystal structure with FES proto-oncogene tyrosine kinase, as a surrogate of FER followed by chemical modification including scaffold hopping of the pyridine template, we discovered pyrido-pyridazinone derivatives with potent FER kinase inhibitory activity. Here, we disclose the structure-activity relationship on the scaffold and representative compound 21 (DS21360717), which showed in vivo antitumor efficacy in a subcutaneous tumor model.

BICYCLIC INHIBITORS OF ALK

The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

Preparation and use of magnesium amides

The present application relates to mixed Mg/Li amides of the general formula ???????? R1R2N-MgX·zLiY?????(I), wherein R1, R2 and R3 independently are selected from substituted or unsubstituted aryl or heteroaryl containing one or more heteroatoms, linear, branched or cyclic, substituted or unsubstituted alkyl, alkenyl, alkynyl, or derivatives thereof, and, for R1 and R2 only, the silyl derivatives thereof; one of R1 and R2 may be H; or R1 and R2 together can be part of a cyclic or polymeric structure; X and Y independently are selected amongst others from the group consisting of F; Cl; Br; I; CN; SCN; NCO; and z > 0, as well as a process for the preparation of the mixed Mg/Li amides and the use of these amides, e.g. as bases.